Incyte (INCY) Capital Leases (2019 - 2026)
Incyte's (INCY) quarterly Capital Leases came in at $28.4 million in Q2 2026, down 10.52% YoY from $31.8 million in Q2 2025, and down 3.38% on a QoQ basis from $29.4 million in Q1 2026.
Incyte (INCY) Capital Leases (2019 - 2026) Analysis & Trends
Incyte (INCY) has 8 years of Capital Leases data on file, last reported at $28.4 million in Q2 2026.
- Quarterly Capital Leases fell 10.52% year-over-year to $28.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.4 million (down 10.52% YoY) and the FY2025 annual result came in at $30.2 million, down 9.97% from the prior year.
- Capital Leases slipped to $28.4 million in Q2 2026, from $29.4 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $33.5 million in Q4 2024 to a low of $28.2 million in Q3 2024.
- A 5-year average of $30.2 million and a median of $29.9 million in 2022 frame the typical range for Capital Leases.
- Annual changes were most pronounced in 2024 — Capital Leases climbed 15.02% — and 2026, when it slipped 10.52%.
- Tracing INCY's Capital Leases over 5 years: stood at $30.1 million in 2022, then slipped by 3.06% to $29.2 million in 2023, then grew by 15.02% to $33.5 million in 2024, then slipped by 9.97% to $30.2 million in 2025, then declined by 5.89% to $28.4 million in 2026.
- The last three Capital Leases figures came in at $28.4 million (Q2 2026), $29.4 million (Q1 2026), and $30.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.42 Mn |
| Mar 31, 2026 | 29.41 Mn |
| Dec 31, 2025 | 30.20 Mn |
| Sep 30, 2025 | 30.88 Mn |
| Jun 30, 2025 | 31.76 Mn |
| Mar 31, 2025 | 32.64 Mn |
| Dec 31, 2024 | 33.54 Mn |
| Sep 30, 2024 | 28.22 Mn |
| Jun 30, 2024 | 28.75 Mn |
| Mar 31, 2024 | 28.93 Mn |
| Dec 31, 2023 | 29.16 Mn |
| Sep 30, 2023 | 28.86 Mn |
| Jun 30, 2023 | 29.49 Mn |
| Mar 31, 2023 | 29.70 Mn |
| Dec 31, 2022 | 30.08 Mn |
| Sep 30, 2022 | 30.48 Mn |
| Jun 30, 2022 | 31.16 Mn |
| Mar 31, 2022 | 31.39 Mn |
| Dec 31, 2021 | 31.63 Mn |
| Sep 30, 2021 | 31.38 Mn |